170 related articles for article (PubMed ID: 20875616)
1. Clinical applications of VEGF-trap (aflibercept) in cancer treatment.
Teng LS; Jin KT; He KF; Zhang J; Wang HH; Cao J
J Chin Med Assoc; 2010 Sep; 73(9):449-56. PubMed ID: 20875616
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept a new target therapy in cancer treatment: a review.
Ricci V; Ronzoni M; Fabozzi T
Crit Rev Oncol Hematol; 2015 Dec; 96(3):569-76. PubMed ID: 26224565
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.
Sharma T; Dhingra R; Singh S; Sharma S; Tomar P; Malhotra M; Bhardwaj TR
Mini Rev Med Chem; 2013 Apr; 13(4):530-40. PubMed ID: 23317499
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
Lockhart AC; Rothenberg ML; Dupont J; Cooper W; Chevalier P; Sternas L; Buzenet G; Koehler E; Sosman JA; Schwartz LH; Gultekin DH; Koutcher JA; Donnelly EF; Andal R; Dancy I; Spriggs DR; Tew WP
J Clin Oncol; 2010 Jan; 28(2):207-14. PubMed ID: 19949018
[TBL] [Abstract][Full Text] [Related]
5. Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?
Jin K; Shen Y; He K; Xu Z; Li G; Teng L
Clin Transl Oncol; 2010 Aug; 12(8):526-32. PubMed ID: 20709650
[TBL] [Abstract][Full Text] [Related]
6. Fusion Proteins: Aflibercept (VEGF Trap-Eye).
Sarwar S; Bakbak B; Sadiq MA; Sepah YJ; Shah SM; Ibrahim M; Do DV; Nguyen QD
Dev Ophthalmol; 2016; 55():282-94. PubMed ID: 26501481
[TBL] [Abstract][Full Text] [Related]
7. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors.
Chu QS
Expert Opin Biol Ther; 2009 Feb; 9(2):263-71. PubMed ID: 19236257
[TBL] [Abstract][Full Text] [Related]
8. Aflibercept--a decoy VEGF receptor.
Ciombor KK; Berlin J
Curr Oncol Rep; 2014 Feb; 16(2):368. PubMed ID: 24445500
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
Sanz-Garcia E; SaurĂ T; Tabernero J; Macarulla T
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Thai HT; Veyrat-Follet C; Mentré F; Comets E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
Browning DJ; Kaiser PK; Rosenfeld PJ; Stewart MW
Am J Ophthalmol; 2012 Aug; 154(2):222-6. PubMed ID: 22813448
[TBL] [Abstract][Full Text] [Related]
12. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept for the treatment of diabetic macular edema.
Harkins KA; Haschke M; Do DV
Immunotherapy; 2016 May; 8(5):503-10. PubMed ID: 26907516
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
15. Aflibercept in lung cancer.
Neal JW; Wakelee HA
Expert Opin Biol Ther; 2013 Jan; 13(1):115-20. PubMed ID: 23199019
[TBL] [Abstract][Full Text] [Related]
16. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity.
Konner J; Dupont J
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S81-5. PubMed ID: 15479484
[TBL] [Abstract][Full Text] [Related]
17. A preclinical and clinical review of aflibercept for the management of cancer.
Gaya A; Tse V
Cancer Treat Rev; 2012 Aug; 38(5):484-93. PubMed ID: 22264850
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye.
Drugs R D; 2008; 9(4):261-9. PubMed ID: 18588357
[No Abstract] [Full Text] [Related]
19. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]